SSG
WST icon

Summit Securities Group’s West Pharmaceutical WST Stock Holding History

Summit Securities Group’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.74K Buy
16
+4
+33% +$1.22K ﹤0.01% 953
2026
Q1 		$3.01K Sell
12
-95
-89% -$23.6K ﹤0.01% 888
2025
Q4 		$29.4K Sell
107
-17
-14% -$4.65K ﹤0.01% 730
2025
Q3 		$32.5K Sell
124
-1,066
-90% -$259K 0.01% 662
2025
Q2 		$260K Buy
+1,190
New +$254K 0.05% 206
2023
Q3 		– Sell
-96
Closed -$37K – 1066
2023
Q2 		$37K Sell
96
-49
-34% -$17.5K ﹤0.01% 479
2023
Q1 		$50K Buy
145
+70
+93% +$20.5K ﹤0.01% 429
2022
Q4 		$18K Buy
75
+58
+341% +$13.7K ﹤0.01% 927
2022
Q3 		$4K Sell
17
-138
-89% -$42K ﹤0.01% 841
2022
Q2 		$47K Buy
155
+124
+400% +$40.3K 0.01% 564
2022
Q1 		$13K Buy
+31
New +$12.1K ﹤0.01% 798

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Summit Securities Group's WST Position: Q2 2026 in Review

Summit Securities Group increased its West Pharmaceutical (WST) stake by 33% in Q2 2026, buying an estimated $1.22K and bringing the position to 16 shares worth $5.74K. The position accounts for ﹤0.01% of the portfolio, ranked #953.

Summit Securities Group first reported a position in WST in Q1 2022 and has held it in 11 quarters since. The position peaked at $260K in Q2 2025. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Summit Securities Group held 16 shares of West Pharmaceutical worth $5.74K as of Q2 2026.
  • Summit Securities Group bought 4 West Pharmaceutical shares in Q2 2026, an estimated $1.22K.
  • West Pharmaceutical made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #953 holding.
  • Summit Securities Group first reported a position in West Pharmaceutical in Q1 2022 and has held it in 11 quarters since.
  • Summit Securities Group's West Pharmaceutical position peaked at $260K in Q2 2025.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.